Influenza and acellular pertussis vaccines not only fail to protect, they increase susceptibility and severity of disease upon infection – benefits are overrated and the risks are being ignored

The influenza vaccine fails often. The influenza vaccines cause the development of IgE mediated
allergy to the influenza virus. The reason for failure include antigenic mismatch between vaccine strain
and wild virus, IgE mediated antigen neutralization, etc. Naturally acquired immunity against influenza
lasts for decades. Vaccine based immunity lasts for a few months. Replacing natural immunity with
vaccine-based immunity, progressively increases susceptibility over time. In 2016-18, between 46 and
68% of patients admitted to the ICU for severe influenza were vaccinated with the influenza vaccine, in
California. The influenza vaccine uptake in the general population in California during that same period
was between 40-48%. This adds to evidence that not only does the influenza vaccine fail, it can
contribute to increased disease severity. The increase in disease severity is due to patients suffering an
allergic reaction against the virus, concurrent with the influenza infection.
The acellular pertussis vaccine (APV) fails to protect for more than a year in most patients, fails to
provide mucosal immunity, fails to provide cell mediated immunity and fails to protect against airway
colonization with Bordetella pertussis (BP) bacteria. Therefore the APV causes asymptomatic
spreading of BP. The exact opposite effect of herd immunity - herd spreading. The APV causes IgE
mediated sensitization directed against BP antigens. Therefore once colonized, continuing exposure to
BP antigens results in asthma. Colonization with BP can cause multiple sclerosis. The APV contains
cow’s milk proteins used to manufacture the vaccine. The milk proteins include bovine casein, bovine
insulin and bovine folate receptor proteins. The result is the development of milk allergy, type 1
diabetes and autism respectively. Colonization can induce immune tolerance to BP, making an infection
even more dangerous and rendering the patient potentially unprotectable for life with a future pertussis
vaccine.